Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05104463 · ClinicalTrials.gov registry record · Phase 2
A Study of CST-2032 and CST-107 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's Disease
A Phase 2 study of Mild Cognitive Impairment and Dementia, sponsored by CuraSen Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
- 15
- Study locations
NCT05104463: Completed Phase 2 study of Mild Cognitive Impairment and Dementia, sponsored by CuraSen Therapeutics.
NCT05104463 is a Phase 2 study of Mild Cognitive Impairment and Dementia that has completed, run by CuraSen Therapeutics. The registered enrollment target is 64 participants, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (95% lower). The trial reports 15 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05104463, a Phase 2 study of Mild Cognitive Impairment and Dementia, has completed, sponsored by CuraSen Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
- 15
- Study locations
Study Summary
This is a Phase 2a, randomized, placebo-controlled, double-blind, crossover study to evaluate the effects CST-2032 administered with CST-107 on cognition in participants with Mild Cognitive Impairment (MCI) or mild dementia.
Primary Outcome
The number of participants experiencing treatment-emergent adverse events after receiving 3mg CST-2032 co-administered with 3mg CST-107 compared to placebo
Conditions Studied
Interventions
- DRUG CST-2032, matching placebo for CST-2032, CST-107, matching placebo for CST-107
Study Locations (15)
Florida
- CuraSen Investigational Site - Boca Raton
- CuraSen Investigational Site - Bradenton
- CuraSen Investigational Site - Lady Lake
- CuraSen Investigational Site - Miami
- CuraSen Investigational Site - New Port Richey
- CuraSen Investigational Site - Winter Park
Texas
- CuraSen Investigational Site - Houston
- CuraSen Investigational Site - Round Rock
- CuraSen Investigational Site - Stafford
Arizona
- CuraSen Investigational Site - Scottsdale
California
- CuraSen Investigational Site - Lafayette
New York
- CuraSen Investigational Site - New York
Ohio
- CuraSen Investigational Site - Cincinnati
Utah
- CuraSen Investigational Site - Salt Lake City
Other
- CuraSen Investigational Site - Christchurch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2022-04-11 |
| Est. Completion | 2024-02-01 |
| Phase | Phase 2 |
What the finished NCT05104463 record still lists
NCT05104463 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Mild Cognitive Impairment appearing as the primary indexed condition, and to 1 intervention - of which CST-2032, matching placebo for CST-2032, CST-107, matching placebo for CST-107 is the first listed.
NCT05104463 lists 15 locations in 8 states (Florida, Texas, Arizona).
Frequently Asked Questions
What is clinical trial NCT05104463 about?
NCT05104463 is a clinical study titled "A Study of CST-2032 and CST-107 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's Disease". This is a Phase 2a, randomized, placebo-controlled, double-blind, crossover study to evaluate the effects CST-2032 administered with CST-107 on cognition in participants with Mild Cognitive Impairment (MCI) or mild dementia.
What is the current status of trial NCT05104463?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2022-04-11. Estimated completion is 2024-02-01.
What conditions does trial NCT05104463 study?
This clinical trial studies the following conditions: Mild Cognitive Impairment, Dementia.
What interventions are being tested in trial NCT05104463?
The interventions under investigation include: CST-2032, matching placebo for CST-2032, CST-107, matching placebo for CST-107 (DRUG).
Who is sponsoring clinical trial NCT05104463?
This trial is sponsored by CuraSen Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05104463 being conducted?
This trial has 15 study locations across Arizona, California, Florida, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mild Cognitive Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05104463's enrollment target sits among peer trials
64 121st of 205 higher than 84 of 205 other Mild Cognitive Impairment trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Mild Cognitive Impairment trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sleep Healthy Using the Internet Mitigating Insomnia to Address Neurocognitive Difficulties (SHUTi MIND)
RECRUITING · Phase 2
-
Evaluate the Effect of Atorvastatin on Cerebrovascular Reactivity in Mild Cognitive Impairment (MCI)
RECRUITING · Phase 2
-
The Caffeine, Postoperative Delirium, and Change in Outcomes After Surgery (CAPACHINOS-2) Study
RECRUITING · Phase 2
-
Rapamycin - Effects on Alzheimer's and Cognitive Health
RECRUITING · Phase 2
-
The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults
RECRUITING · Phase 2
-
Pathways Relating Amnestic MCI to a Mild Traumatic Brain Injury History
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI